Tumor Type Bone marrow leukemia non- Patient Name Report Date lymphocytic acute myelocytic (AML) Date of Birth Medical Facility Specimen Received Sex Ordering Physician Specimen Site FMI Case # SRF201611 Additional Recipient Date of Collection Medical Record # Medical Facility ID # Specimen Type Specimen ID Pathologist ABOUT THE TEST: FoundationOne Heme™ is a next-generation sequencing (NGS) based assay that identifies genomic alterations within hundreds of cancer-related genes. TUMOR TYPE: BONE MARROW LEUKEMIA NON- PATIENT RESULTS‖ LYMPHOCYTIC ACUTE MYELOCYTIC (AML) 4 genomic alterations Genomic Alterations Identified† FLT3 FLT3-ITD (R595_E596ins16) 5 therapies associated with potential clinical benefit NF1 L2149fs*20 NPM1 W288fs*10+ 0 therapies associated with lack of response PTPN11 N308D – subclonal⧺ 8 clinical trials II Reduced sensitivity due to sample quality – See Appendix: Performance Specifications for details. † For a complete list of the genes assayed and performance specifications, please refer to the Appendix ⧺ See Appendix for details THERAPEUTIC IMPLICATIONS Genomic Alterations FDA-Approved Therapies FDA-Approved Therapies Potential Clinical Trials Detected (in patient’s tumor type) (in another tumor type) FLT3 None Ponatinib Yes, see clinical trials FLT3-ITD (R595_E596ins16) Sorafenib section Sunitinib NF1 None Cobimetinib Yes, see clinical trials L2149fs*20 Trametinib section NPM1 None None None W288fs*10+ PTPN11 None None None N308D - subclonal Note: Genomic alterations detected may be associated with activity of certain FDA-approved drugs; however, the agents listed in this report may have little or no evidence in the patient’s tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for SAMPLEthis patient, nor are they ranked in order of level of evidence for this patient’s tumor type. For more comprehensive information please log on to the Interactive Cancer Explorer™ To set up your Interactive Cancer Explorer account, contact your sales representative or call (888) 988-3639. Electronically Signed by Julia A. Elvin, M.D., Ph.D. | Jeffrey S. Ross, M.D., Medical Director | CLIA Number: 22D2027531 | 05 July 2016 Foundation Medicine, Inc., 150 2nd Street, 1st Floor, Cambridge, MA 02141 | 1.888.988.3639 page 1 of 22 Tumor Type Bone marrow leukemia non- Patient Name Report Date lymphocytic acute myelocytic (AML) GENOMIC ALTERATIONS GENE INTERPRETATION ALTERATION FLT3 Gene and Alteration: FLT3 encodes a receptor tyrosine kinase. Signaling through the FLT3 pathway FLT3-ITD leads to phosphorylation of Shc1 and AKT1 and activation of mTOR, as well as RAS activation and (R595_E596ins16) phosphorylation of ERK1/21,2,3. The FLT3 internal tandem duplication (FLT3-ITD) observed here is predicted to be activating4,5,6. FLT3-ITD are frequent in acute myeloid leukemia (AML) and are associated with poor prognosis, as well as having implications for risk stratification in patients with normal karyotype7,8,9,10. Frequency and Prognosis: In the TCGA dataset, FLT3 mutation was observed in 27% of acute myeloid leukemia (AML) cases11. FLT3-ITDs have been reported in 31% of cases and mutations of the tyrosine kinase domain specifically in 11% of cases9. FLT3-ITDs in patients with AML are associated with poor prognosis as well as having implications for risk stratification in patients with normal karyotype7,8,9,10. Potential Treatment Strategies: Therapies targeting FLT3 are under clinical investigation, including sorafenib, ponatinib, sunitinib, crenolanib, midostaurin, quizartinib, lestaurtinib, gilteritinib, and pexidartinib12,13,14. The addition of sorafenib to standard chemotherapy regimens (Uy et al., 2015; ASH Abstract 319)15, hematopoietic cell transplant regimens (Brunner et al., 2015; ASH Abstract 864)16,17,18 or hypomethylating agents19,20 has resulted in clinical efficacy for patients with AML and FLT3-ITD. In a Phase 1 trial of 12 patients with AML, ponatinib elicited an overall response rate (RR) of 30% (3/10) in patients with FLT3-ITD, with a higher RR (43%, 3/7) observed in patients who were FLT3 inhibitor- naive21. In another Phase 1 trial, 4/4 patients with AML harboring activating FLT3 mutations exhibited morphologic or partial responses to sunitinib22. Crenolanib has shown preclinical efficacy against tumors harboring FLT3 alterations, including mutations at D835 (FLT3-TKD) that confer resistance to sorafenib and sunitinib23,23,24,25,26,27,28. The Phase 3 RATIFY trial reported that addition of midostaurin improved overall survival (OS) for patients with AML and FLT3-ITDs or FLT3-TKDs relative to treatment with standard chemotherapy alone (Stone et al., 2015; ASH Abstract 6). Quizartinib is also being investigated for patients with AML and FLT3-ITDs and resulted in composite complete remission (CRc) in 43% of cases versus 11% in historical controls in a Phase 2 trial (Hills et al., 2015; ASH Abstract 2557). In Phase 1/2 trials of gilteritinib for AML, overall responses (ORs) were observed in 57-63% of patients with unspecified FLT3 mutations (Levis et al., 2015; ASCO Abstract 7003) and in 60% (68/114) of those with FLT3-ITDs only (Altman et al., 2015; ASH Abstract 321). NF1 Gene and Alteration: NF1 encodes neurofibromin, a GTPase-activating protein (GAP) that is a key L2149fs*20 negative regulator of the RAS signaling pathway29. Neurofibromin acts as a tumor suppressor by repressing RAS signaling30. Although this alteration has not been fully characterized and its effect on NF1 function is unclear, it has been previously reported in the context of cancer, which may indicate biological relevance. Germline mutations in NF1 cause the autosomal dominant disorder neurofibromatosis type 1, which is characterized in part by increased risk of developing various tumors, including sarcoma, glioma, breast carcinoma, and neuroendocrine and hematological neoplasms31,32,33. Estimates for the prevalence of the disorder in the general population range from 1:2,500 to 1:3,00034,35, and in the appropriate clinical context, germline testing of NF1 is recommended. Frequency and Prognosis: NF1 mutation has been reported in 1-7% of AML samples analyzed, which has been suggested to represent a subset of AML cases that may benefit from therapies with mTOR SAMPLEinhibitors (COSMIC, cBioPortal, Jan 2016)36,37,38. For more comprehensive information please log on to the Interactive Cancer Explorer™ To set up your Interactive Cancer Explorer account, contact your sales representative or call (888) 988-3639. Electronically Signed by Julia A. Elvin, M.D., Ph.D. | Jeffrey S. Ross, M.D., Medical Director | CLIA Number: 22D2027531 | 05 July 2016 Foundation Medicine, Inc., 150 2nd Street, 1st Floor, Cambridge, MA 02141 | 1.888.988.3639 page 2 of 22 Tumor Type Bone marrow leukemia non- Patient Name Report Date lymphocytic acute myelocytic (AML) GENE INTERPRETATION ALTERATION Potential Treatment Strategies: On the basis of clinical evidence from a Phase 1 study in neurofibromatosis type 1 (Widemann et al., 2014; ASCO Abstract 10018) and a case report in neurofibromatosis-associated glioblastoma39 as well as extensive preclinical evidence in several tumor types40,41,42,43,44, NF1 inactivation may predict sensitivity to MEK inhibitors, including the approved therapies cobimetinib and trametinib. Loss or inactivation of NF1 may also predict sensitivity to mTOR inhibitors, including the approved agents everolimus and temsirolimus, based on limited clinical data45,46,47 and strong preclinical data in models of malignant peripheral nerve sheath tumor (MPNST)48,49. These and other relevant compounds are being investigated in clinical trials. Limited clinical and preclinical evidence in melanoma suggest that in the context of BRAF mutation, NF1 loss or inactivation may reduce sensitivity to BRAF inhibitors41,50,51; data are conflicting on whether NF1 deficiency reduces sensitivity to MEK inhibition in BRAF-mutant melanoma41,50,52,53. Although a preclinical study suggests that combined mTOR and MEK inhibition is effective in a model of NF1- deficient MPNST54, a Phase 1b trial of a combination of the mTOR inhibitor everolimus and the MEK inhibitor trametinib in patients with solid tumors reported frequent adverse events and was unable to identify a recommended Phase 2 dose and schedule for the combination55. However, it is not known whether these therapeutic approaches would be relevant in the context of alterations that have not been fully characterized, as seen here. NPM1 Gene and Alteration: NPM1 encodes nucleophosmin, a protein involved in numerous critical cellular W288fs*10+ processes including the regulation of tumor suppressors such as p53 and ARF. NPM1 expression is elevated in many tumors, leading to enhanced c-MYC transformation; low NPM1 expression is associated with suppressed tumor growth. Thus, depending on the cellular level of NPM1, it may act as a proto-oncogene or a tumor suppressor56,57. The NPM1 truncating alteration observed here is similar to mutations that have been repeatedly observed in the context of acute myeloid leukemia (AML) and are known to be deleterious to NPM1 function58,59,60,61. Frequency and Prognosis: In the TCGA dataset, NPM1 mutation was observed in 27% of AML samples analyzed11. Abnormal cytoplasmic localization of nucleophosmin has been observed in 35% of AML cases, and analysis of 52 NPM1 mutations found all but one to be located in the last coding exon, exon 1260. Exon 12 mutations interrupting the nuclear localization signal of nucleophosmin